{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:02:07Z","timestamp":1768888927033,"version":"3.49.0"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.atherosclerosis.2016.02.018","type":"journal-article","created":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T17:02:45Z","timestamp":1457542965000},"page":"62-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?"],"prefix":"10.1016","volume":"248","author":[{"given":"Yajnavalka","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9860-6582","authenticated-orcid":false,"given":"Raul D.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Al-Rasadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"36","key":"10.1016\/j.atherosclerosis.2016.02.018_bib1","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1093\/eurheartj\/ehv174","article-title":"PCSK9 (Proprotein convertase subtilisin\/kexin type 9) inhibitors: past, present, and the future","volume":"36","author":"Shimada","year":"2015","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.02.018_bib2","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","article-title":"PCSK9: a key modulator of cardiovascular health","volume":"114","author":"Seidah","year":"2014","journal-title":"Circ. Res."},{"issue":"16","key":"10.1016\/j.atherosclerosis.2016.02.018_bib3","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"16","key":"10.1016\/j.atherosclerosis.2016.02.018_bib4","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.02.018_bib5","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2016.02.018_bib6","unstructured":"FDA approves second in new class of cholesterol lowering drugs, accessed on 3\/7\/2016. http:\/\/edition.cnn.com\/2015\/08\/27\/health\/fda-new-cholesterol-drug-repatha\/index.html."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.018_bib7","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jacl.2015.01.001","article-title":"Understanding PCSK9 and anti-PCSK9 therapies","volume":"9","author":"McKenney","year":"2015","journal-title":"J.\u00a0Clin. Lipidol."},{"issue":"47","key":"10.1016\/j.atherosclerosis.2016.02.018_bib8","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.02.018_bib9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5001\/omj.2013.11","article-title":"Mutation in the PCSK9 gene in Omani Arab subjects with autosomal dominant hypercholesterolemia and its effect on PCSK9 protein structure","volume":"28","author":"Al-Waili","year":"2013","journal-title":"Oman Med. J."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.02.018_bib10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/humu.9383","article-title":"Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia","volume":"26","author":"Allard","year":"2005","journal-title":"Hum. Mutat."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.018_bib11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.018_bib12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/humu.20201","article-title":"LOVD: easy creation of a locus-specific sequence variation database using an \u201cLSDB-in-a-box\u201d approach","volume":"26","author":"Fokkema","year":"2005","journal-title":"Hum. Mutat."},{"issue":"6895","key":"10.1016\/j.atherosclerosis.2016.02.018_bib13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1136\/bmj.307.6895.66-a","article-title":"Searching the literature. Be systematic in your searching","volume":"307","author":"Jadad","year":"1993","journal-title":"BMJ"},{"issue":"42","key":"10.1016\/j.atherosclerosis.2016.02.018_bib14","doi-asserted-by":"crossref","first-page":"28856","DOI":"10.1074\/jbc.M109.037085","article-title":"Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route","volume":"284","author":"Poirier","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.02.018_bib15","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/embor.2011.205","article-title":"Mechanistic implications for LDL receptor degradation from the PCSK9\/LDLR structure at neutral pH","volume":"12","author":"Lo","year":"2011","journal-title":"EMBO Rep."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.02.018_bib16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11883-013-0310-3","article-title":"Potential of proprotein convertase subtilisin\/kexin type 9 based therapeutics","volume":"15","author":"Stein","year":"2013","journal-title":"Curr. Atheroscler. Rep."},{"issue":"24","key":"10.1016\/j.atherosclerosis.2016.02.018_bib17","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.113.001592","article-title":"Serum proprotein convertase subtilisin\/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation","volume":"127","author":"Tavori","year":"2013","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2016.02.018_bib18","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1586\/14779072.2013.839204","article-title":"PCSK9 and resistin at the crossroads of the atherogenic dyslipidemia","volume":"11","author":"Rashid","year":"2013","journal-title":"Expert Rev. Cardiovasc Ther."},{"key":"10.1016\/j.atherosclerosis.2016.02.018_bib19","article-title":"PCSK9 and triglyceride-rich lipoprotein metabolism","volume":"29","author":"Druce","year":"2015","journal-title":"J.\u00a0Biomed. Res."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.018_bib20","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.atherosclerosis.2014.12.017","article-title":"On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects","volume":"238","author":"Tavori","year":"2015","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.02.018_bib21","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1210\/en.2005-0894","article-title":"Minireview: regulation of epithelial Na+ channel trafficking","volume":"146","author":"Snyder","year":"2005","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.02.018_bib22","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/0092-8674(95)90212-0","article-title":"Mechanism by which Liddle's syndrome mutations increase activity of a human epithelial Na+ channel","volume":"83","author":"Snyder","year":"1995","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.atherosclerosis.2016.02.018_bib23","doi-asserted-by":"crossref","first-page":"19266","DOI":"10.1074\/jbc.M112.363382","article-title":"Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin\/kexin type 9 (PCSK9)","volume":"287","author":"Sharotri","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.02.018_bib24","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.atherosclerosis.2015.01.012","article-title":"PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension","volume":"239","author":"Berger","year":"2015","journal-title":"Atherosclerosis"},{"issue":"9836","key":"10.1016\/j.atherosclerosis.2016.02.018_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.atherosclerosis.2016.02.018_bib26","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"20","key":"10.1016\/j.atherosclerosis.2016.02.018_bib27","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.atherosclerosis.2016.02.018_bib28","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.jacc.2012.08.986","article-title":"Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins","volume":"60","author":"Dias","year":"2012","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"9965","key":"10.1016\/j.atherosclerosis.2016.02.018_bib29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"9965","key":"10.1016\/j.atherosclerosis.2016.02.018_bib30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.018_bib31","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.018_bib32","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/hep.26184","article-title":"Association between liver-specific gene polymorphisms and their expression levels with nonalcoholic fatty liver disease","volume":"57","author":"Adams","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.02.018_bib33","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jhep.2004.01.028","article-title":"Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis","volume":"40","author":"Namikawa","year":"2004","journal-title":"J.\u00a0Hepatol."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2016.02.018_bib34","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.bbadis.2011.07.017","article-title":"Genetic modifiers of non-alcoholic fatty liver disease progression","volume":"1812","author":"Anstee","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2016.02.018_bib35","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/j.1478-3231.2006.01323.x","article-title":"Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease","volume":"26","author":"Day","year":"2006","journal-title":"Liver Int."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.02.018_bib36","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.febslet.2009.12.018","article-title":"PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities","volume":"584","author":"Mbikay","year":"2010","journal-title":"FEBS Lett."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.02.018_bib37","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bbrc.2009.10.138","article-title":"PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion","volume":"390","author":"Langhi","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2016.02.018_bib38","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s00125-015-3659-8","article-title":"The loss-of-function PCSK9\u00a0p.R46L genetic variant does not alter glucose homeostasis","volume":"58","author":"Bonnefond","year":"2015","journal-title":"Diabetologia"},{"issue":"9716","key":"10.1016\/j.atherosclerosis.2016.02.018_bib39","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.02.018_bib40","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrgastro.2009.32","article-title":"Mechanisms of HCV survival in the host","volume":"6","author":"Sklan","year":"2009","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.02.018_bib41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hep.22911","article-title":"PCSK9 impedes hepatitis C virus infection in\u00a0vitro and modulates liver CD81 expression","volume":"50","author":"Labonte","year":"2009","journal-title":"Hepatology"},{"issue":"43","key":"10.1016\/j.atherosclerosis.2016.02.018_bib42","doi-asserted-by":"crossref","first-page":"41624","DOI":"10.1074\/jbc.M305289200","article-title":"Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor","volume":"278","author":"Bartosch","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"issue":"25","key":"10.1016\/j.atherosclerosis.2016.02.018_bib43","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMc1204929","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Milazzo","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.018_bib44","doi-asserted-by":"crossref","first-page":"e1000010","DOI":"10.1371\/journal.ppat.1000010","article-title":"Hepatocyte permissiveness to Plasmodium infection is conveyed by a short and structurally conserved region of the CD81 large extracellular domain","volume":"4","author":"Yalaoui","year":"2008","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.02.018_bib45","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nm808","article-title":"Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity","volume":"9","author":"Silvie","year":"2003","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.02.018_bib46","doi-asserted-by":"crossref","first-page":"e64145","DOI":"10.1371\/journal.pone.0064145","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)","volume":"8","author":"Canuel","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.02.018_bib47","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/jcp.22130","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells","volume":"224","author":"Lan","year":"2010","journal-title":"J.\u00a0Cell Physiol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.02.018_bib48","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.cell.2011.10.026","article-title":"Autophagy: renovation of cells and tissues","volume":"147","author":"Mizushima","year":"2011","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.018_bib49","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1517\/17425247.2014.952627","article-title":"Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody","volume":"12","author":"Pardridge","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2016.02.018_bib50","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/jcbfm.2011.197","article-title":"Neurological diseases in relation to the blood-brain barrier","volume":"32","author":"Rosenberg","year":"2012","journal-title":"J.\u00a0Cereb. Blood Flow. Metab."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2016.02.018_bib51","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1161\/STROKEAHA.111.615559","article-title":"Increased blood-brain barrier permeability and brain edema after focal cerebral ischemia induced by hyperlipidemia: role of lipid peroxidation and calpain-1\/2, matrix metalloproteinase-2\/9, and RhoA overactivation","volume":"42","author":"ElAli","year":"2011","journal-title":"Stroke"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2016.02.018_bib52","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1080\/14647270802336650","article-title":"Influence of hypercholesterolemia and hypertension on the integrity of the blood-brain barrier in rats","volume":"119","author":"Kalayci","year":"2009","journal-title":"Int. J. Neurosci."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2016.02.018_bib53","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/cyto.a.20346","article-title":"Proapoptotic effects of NARC 1 (= PCSK9), the gene encoding a novel serine proteinase","volume":"69","author":"Bingham","year":"2006","journal-title":"Cytom. A"},{"issue":"1\u20132","key":"10.1016\/j.atherosclerosis.2016.02.018_bib54","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11010-011-1028-6","article-title":"PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl\/Bax-caspase9-caspase3 pathway","volume":"359","author":"Wu","year":"2012","journal-title":"Mol. Cell Biochem."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2016.02.018_bib55","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s00018-012-0977-6","article-title":"PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling","volume":"69","author":"Kysenius","year":"2012","journal-title":"Cell Mol. Life Sci."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.02.018_bib56","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2016.02.018_bib57","series-title":"FDA Advises of Adverse Effects from New Cholesterol Drugs","author":"Walker","year":"2014"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.02.018_bib58","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1600-0854.2012.01332.x","article-title":"Membrane trafficking pathways in Alzheimer's disease","volume":"13","author":"Rajendran","year":"2012","journal-title":"Traffic"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.02.018_bib59","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1042\/BJ20070040","article-title":"A\u00a0reversible form of lysine acetylation in the ER and Golgi lumen controls the molecular stabilization of BACE1","volume":"407","author":"Costantini","year":"2007","journal-title":"Biochem. J."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2016.02.018_bib60","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/sj.emboj.7601062","article-title":"An aging pathway controls the TrkA to p75NTR receptor switch and amyloid beta-peptide generation","volume":"25","author":"Costantini","year":"2006","journal-title":"EMBO J."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2016.02.018_bib61","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/embor.2008.132","article-title":"PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1","volume":"9","author":"Jonas","year":"2008","journal-title":"EMBO Rep."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2016.02.018_bib62","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1194\/jlr.M006635","article-title":"PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain","volume":"51","author":"Liu","year":"2010","journal-title":"J.\u00a0Lipid Res."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.018_bib63","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3892\/br.2013.213","article-title":"The dual behavior of PCSK9 in the regulation of apoptosis is crucial in Alzheimer's disease progression (Review)","volume":"2","author":"Wu","year":"2014","journal-title":"Biomed. Rep."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.02.018_bib64","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of Proprotein convertase subtilisin\/kexin Type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann. Intern Med."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.02.018_bib65","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbrc.2008.07.106","article-title":"PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide","volume":"375","author":"Shan","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.018_bib66","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.chembiol.2013.11.014","article-title":"Design and synthesis of truncated EGF-A peptides that restore LDL-R recycling in the presence of PCSK9 in\u00a0vitro","volume":"21","author":"Schroeder","year":"2014","journal-title":"Chem. Biol."},{"issue":"50","key":"10.1016\/j.atherosclerosis.2016.02.018_bib67","doi-asserted-by":"crossref","first-page":"43054","DOI":"10.1074\/jbc.M111.273474","article-title":"Novel domain interaction regulates secretion of proprotein convertase subtilisin\/kexin type 9 (PCSK9) protein","volume":"286","author":"Du","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.018_bib68","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1074\/jbc.M113.514067","article-title":"Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor","volume":"289","author":"Zhang","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.02.018_bib69","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1006\/jmbi.1998.2238","article-title":"The fibronectin type III domain as a scaffold for novel binding proteins","volume":"284","author":"Koide","year":"1998","journal-title":"J.\u00a0Mol. Biol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.02.018_bib70","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nsmb.1793","article-title":"A\u00a0potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain","volume":"17","author":"Wojcik","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"25","key":"10.1016\/j.atherosclerosis.2016.02.018_bib71","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation","volume":"282","author":"Zhang","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2016.02.018_bib72","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J.\u00a0Clin. Invest"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.018_bib73","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1124\/jpet.114.214221","article-title":"Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering","volume":"350","author":"Mitchell","year":"2014","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"issue":"12_S","key":"10.1016\/j.atherosclerosis.2016.02.018_bib74","article-title":"LDL Cholesterol reduction with BMS-962476, an adnectin inhibitor of PCSK9: results of a single ascending dose study","volume":"63","author":"Stein","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.02.018_bib75","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0022-3565(24)37605-0","article-title":"In\u00a0vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration","volume":"286","author":"Graham","year":"1998","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2016.02.018_bib76","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/78475","article-title":"Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis","volume":"18","author":"Zhang","year":"2000","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.02.018_bib77","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0022-3565(24)38831-7","article-title":"Pharmacokinetic properties of 2\u2032-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats","volume":"296","author":"Geary","year":"2001","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"issue":"18","key":"10.1016\/j.atherosclerosis.2016.02.018_bib78","doi-asserted-by":"crossref","first-page":"11994","DOI":"10.1074\/jbc.272.18.11994","article-title":"2\u2032-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells","volume":"272","author":"Baker","year":"1997","journal-title":"J.\u00a0Biol. Chem."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.02.018_bib79","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1194\/jlr.C600025-JLR200","article-title":"Antisense inhibition of proprotein convertase subtilisin\/kexin type 9 reduces serum LDL in hyperlipidemic mice","volume":"48","author":"Graham","year":"2007","journal-title":"J.\u00a0Lipid Res."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.018_bib80","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/mt.2011.260","article-title":"PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates","volume":"20","author":"Lindholm","year":"2012","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.02.018_bib81","doi-asserted-by":"crossref","first-page":"e10682","DOI":"10.1371\/journal.pone.0010682","article-title":"A\u00a0locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in\u00a0vitro and in\u00a0vivo","volume":"5","author":"Gupta","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.02.018_bib82","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/jps.10473","article-title":"Tissue disposition of 2\u2032-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys","volume":"93","author":"Yu","year":"2004","journal-title":"J.\u00a0Pharm. Sci."},{"issue":"5441","key":"10.1016\/j.atherosclerosis.2016.02.018_bib83","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1126\/science.286.5441.950","article-title":"A\u00a0species of small antisense RNA in posttranscriptional gene silencing in plants","volume":"286","author":"Hamilton","year":"1999","journal-title":"Science"},{"issue":"33","key":"10.1016\/j.atherosclerosis.2016.02.018_bib84","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates","volume":"105","author":"Frank-Kamenetsky","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.02.018_bib85","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nbt.2842","article-title":"CRISPR-Cas systems for editing, regulating and targeting genomes","volume":"32","author":"Sander","year":"2014","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2016.02.018_bib86","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/CIRCRESAHA.115.304351","article-title":"Permanent alteration of PCSK9 with in\u00a0vivo CRISPR-Cas9 genome editing","volume":"115","author":"Ding","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2016.02.018_bib87","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/978-1-60761-688-7_27","article-title":"Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity","volume":"640","author":"Strom","year":"2010","journal-title":"Methods Mol. Biol."},{"issue":"7546","key":"10.1016\/j.atherosclerosis.2016.02.018_bib88","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In\u00a0vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2016.02.018_bib89","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/mt.2008.174","article-title":"Targeting of adenovirus vectors to the LRP receptor family with the high-affinity ligand RAP via combined genetic and chemical modification of the pIX capsomere","volume":"16","author":"Corjon","year":"2008","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.02.018_bib90","doi-asserted-by":"crossref","first-page":"e114469","DOI":"10.1371\/journal.pone.0114469","article-title":"Peptide-based anti-PCSK9 vaccines \u2013 an approach for long-term LDLc management","volume":"9","author":"Galabova","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.02.018_bib91","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/pr.112.005660","article-title":"Strategies to address low drug solubility in discovery and development","volume":"65","author":"Williams","year":"2013","journal-title":"Pharmacol. Rev."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.02.018_bib92","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/embor.2011.205","article-title":"Mechanistic implications for LDL receptor degradation from the PCSK9\/LDLR structure at neutral pH","volume":"12","author":"Lo","year":"2011","journal-title":"EMBO Rep."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.02.018_bib93","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1194\/jlr.E800008-JLR200","article-title":"PCSK9 function and physiology","volume":"49","author":"Peterson","year":"2008","journal-title":"J.\u00a0Lipid Res."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.018_bib94","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1074\/jbc.M808363200","article-title":"Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants","volume":"284","author":"Bottomley","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"issue":"25","key":"10.1016\/j.atherosclerosis.2016.02.018_bib95","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMc1204929","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Banerjee","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.018_bib96","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.018_bib97","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.atherosclerosis.2012.04.006","article-title":"Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia","volume":"223","author":"Abifadel","year":"2012","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.02.018_bib98","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1161\/ATVBAHA.111.240549","article-title":"Common and low-frequency genetic variants in the PCSK9 locus influence circulating PCSK9 levels","volume":"32","author":"Chernogubova","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.02.018_bib99","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1373\/clinchem.2009.129759","article-title":"Healthy individuals carrying the PCSK9\u00a0p.R46L variant and familial hypercholesterolemia patients carrying PCSK9\u00a0p.D374Y exhibit lower plasma concentrations of PCSK9","volume":"55","author":"Humphries","year":"2009","journal-title":"Clin. Chem."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2016.02.018_bib100","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.018_bib101","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.atherosclerosis.2010.09.027","article-title":"Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population","volume":"213","author":"Cui","year":"2010","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2016.02.018_bib102","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1373\/clinchem.2009.126987","article-title":"Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents","volume":"55","author":"Baass","year":"2009","journal-title":"Clin. Chem."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.02.018_bib103","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/ATVBAHA.110.214130","article-title":"Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans","volume":"30","author":"Persson","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.02.018_bib104","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2215\/CJN.05170511","article-title":"Cholesterol synthesis, cholesterol absorption, and mortality in hemodialysis patients","volume":"7","author":"Rogacev","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.018_bib105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.tem.2011.10.004","article-title":"SREBPs: metabolic integrators in physiology and metabolism","volume":"23","author":"Jeon","year":"2012","journal-title":"Trends Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2016.02.018_bib106","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.abb.2010.06.004","article-title":"Sterol metabolism and SREBP activation","volume":"501","author":"Sato","year":"2010","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.atherosclerosis.2016.02.018_bib107","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1038\/ncomms3883","article-title":"MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice","volume":"4","author":"Horie","year":"2013","journal-title":"Nat. Commun."},{"issue":"27","key":"10.1016\/j.atherosclerosis.2016.02.018_bib108","doi-asserted-by":"crossref","first-page":"12228","DOI":"10.1073\/pnas.1005191107","article-title":"miR-33 links SREBP-2 induction to repression of sterol transporters","volume":"107","author":"Marquart","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.02.018_bib109","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1194\/jlr.M800027-JLR200","article-title":"Plasma PCSK9 preferentially reduces liver LDL receptors in mice","volume":"49","author":"Grefhorst","year":"2008","journal-title":"J.\u00a0Lipid Res."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2016.02.018_bib110","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1161\/ATVBAHA.112.250043","article-title":"Proprotein convertase subtilisin\/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor","volume":"32","author":"Sun","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2016.02.018_bib111","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/0092-8674(87)90510-1","article-title":"A\u00a0novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine","volume":"50","author":"Powell","year":"1987","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.02.018_bib112","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/S0022-2275(20)30032-8","article-title":"Secretion from cell culture of HDL and VLDL bearing apoB-33 with a large internal deletion","volume":"38","author":"Wu","year":"1997","journal-title":"J.\u00a0Lipid Res."},{"issue":"31","key":"10.1016\/j.atherosclerosis.2016.02.018_bib113","doi-asserted-by":"crossref","first-page":"19843","DOI":"10.1016\/S0021-9258(17)32097-5","article-title":"Expression and characterization of p27, the catalytic subunit of the apolipoprotein B mRNA editing enzyme","volume":"269","author":"Driscoll","year":"1994","journal-title":"J.\u00a0Biol. Chem."},{"issue":"13","key":"10.1016\/j.atherosclerosis.2016.02.018_bib114","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials","volume":"63","author":"Raal","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"issue":"18","key":"10.1016\/j.atherosclerosis.2016.02.018_bib115","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1074\/jbc.M114.611988","article-title":"Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin\/kexin type 9 through the low density lipoprotein receptor","volume":"290","author":"Romagnuolo","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2016.02.018_bib116","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00041433-200106000-00006","article-title":"Living up to a name: the role of the VLDL receptor in lipid metabolism","volume":"12","author":"Tacken","year":"2001","journal-title":"Curr. Opin. Lipidol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2016.02.018_bib117","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/ATVBAHA.110.220988","article-title":"Circulating proprotein convertase subtilisin\/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue","volume":"31","author":"Roubtsova","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"18","key":"10.1016\/j.atherosclerosis.2016.02.018_bib118","doi-asserted-by":"crossref","first-page":"8453","DOI":"10.1073\/pnas.92.18.8453","article-title":"Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipoprotein receptor","volume":"92","author":"Frykman","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2016.02.018_bib119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(02)00251-4","article-title":"LDL apheresis","volume":"167","author":"Thompson","year":"2003","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2016.02.018_bib120","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1161\/CIRCRESAHA.113.302655","article-title":"Loss of plasma proprotein convertase subtilisin\/kexin 9 (PCSK9) after lipoprotein apheresis","volume":"113","author":"Tavori","year":"2013","journal-title":"Circ. Res."},{"issue":"9965","key":"10.1016\/j.atherosclerosis.2016.02.018_bib121","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(14)61702-5","article-title":"Familial hypercholesterolaemia: PCSK9 inhibitors are coming","volume":"385","author":"Santos","year":"2015","journal-title":"Lancet"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016300612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016300612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T18:18:16Z","timestamp":1748801896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915016300612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":121,"alternative-id":["S0021915016300612"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.02.018","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}